

13. Cirillo F, Vismarra M, Cafaro I, Martinotti M. Merkel cell carcinoma: a retrospective study on 48 cases and review of literature. *J Oncol*. 2012;749030.
14. Hamiditabar M, Ali M, Roys J, et al. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-Octreotate in patients with somatostatin receptor expressing neuroendocrine tumors: six years' assessment. *Clin Nucl Med*. 2017;42:436-443.
15. Schmidt MC, Uhrhan K, Markiefka B, et al. (68)Ga-DotaTATE PET-CT followed by peptide receptor radiotherapy in combination with capecitabine in two patients with Merkel cell carcinoma. *Int J Clin Exp Med*. 2012;5:363-366.
16. Salavati A, Prasad V, Schneider CP, Herbst R, Baum RP. Peptide receptor radionuclide therapy of Merkel cell carcinoma using (177)lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. *Ann Nucl Med*. 2012;26:365-369.
17. Kasi PM, Sharma A, Jain MK. Expanding the indication for novel theranostic ¹⁷⁷Lu-Dotatate peptide receptor radionuclide therapy: proof-of-concept of PRRT in Merkel cell cancer. *Case Rep Oncol*. 2019;12:98-103.
18. Ferdinandus J, Fendler WP, Lueckerath K, et al. Response to combined peptide receptor radionuclide therapy and checkpoint immunotherapy with ipilimumab plus nivolumab in metastatic Merkel cell carcinoma. *J Nucl Med*. September 02, 2021 [Epub a head of print].
19. Sindrilaru A, Aicher A, Crisan D, Prasad V. Use of the low-dose hyperfractionated ¹⁷⁷Lu-HA-DOTATATE peptide receptor radionuclide therapy in patients with immunotherapy-refractory Merkel cell carcinoma-testing of the therapeutic concept in two patients with metastatic Merkel cell carcinoma. *J Dtsch Dermatol Ges*. 2021;19: 20-21.
20. Stefanova M, Kratochwil C, Schwartz L, Haberkorn U, Giesel F. Impact of normal tissue uptake using ⁶⁸Ga DOTATOC-PET/CT in patients with neuroendocrine tumor: a follow-up study. *Insights Imaging*. 2012;3:S160-S161.
21. Koukouraki S, Strauss LG, Georgoulas V, et al. Evaluation of the pharmacokinetics of ⁶⁸Ga-DOTATOC in patients with metastatic neuroendocrine tumors scheduled for ⁹⁰Y-DOTATOC therapy. *Eur J Nucl Med Mol Imaging*. 2006;33:460-466.
22. Epstude M, Tornquist K, Riklin C, et al. Comparison of (18)F-FDG PET/CT and (68)Ga-DOTATATE PET/CT imaging in metastasized Merkel cell carcinoma. *Clin Nucl Med*. 2013;38:283-284.